Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Research & Development (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Research & Development for 6 consecutive years, with $24.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 111.78% to $24.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $72.0 million, a 57.53% increase, with the full-year FY2025 number at $72.0 million, up 57.53% from a year prior.
  • Research & Development was $24.5 million for Q4 2025 at GeneDx Holdings, up from $19.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $53.1 million in Q1 2021 to a low of $10.9 million in Q2 2024.
  • A 5-year average of $18.4 million and a median of $14.8 million in 2023 define the central range for Research & Development.
  • Biggest YoY gain for Research & Development was 127.31% in 2022; the steepest drop was 59.88% in 2022.
  • GeneDx Holdings' Research & Development stood at $22.2 million in 2021, then grew by 9.53% to $24.4 million in 2022, then crashed by 49.73% to $12.2 million in 2023, then dropped by 5.39% to $11.6 million in 2024, then soared by 111.78% to $24.5 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Research & Development are $24.5 million (Q4 2025), $19.8 million (Q3 2025), and $15.1 million (Q2 2025).